Trials / Completed
CompletedNCT00431106
Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer
A Multicenter Randomized Phase III Study of Combination Treatment With Vinorelbine and Gemcitabine Versus Capecitabine Monotherapy in Metastatic Breast Cancer Patients Following Treatment Failure With the Combination of a Taxane and an Anthracycline
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Hellenic Oncology Research Group · Academic / Other
- Sex
- Female
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The combination of vinorelbine and gemcitabine seems to be an important part of the chemotherapy regimens used in metastatic breast cancer patients following treatment failure with the combination of a taxane and an anthracycline. Capecitabine rescue monotherapy in metastatic breast cancer patients following treatment failure with the combination of a taxane and an anthracycline, also seems to be an important part of the chemotherapy regimens used in metastatic breast cancer patients. Whether the combination of vinorelbine and gemcitabine or capecitabine administration is preferable is not yet known, especially in patients with metastatic disease.
Detailed description
This trial will compare the efficacy of combination treatment with Vinorelbine and Gemcitabine versus Capecitabine monotherapy in metastatic breast cancer patients following treatment failure with the combination of a taxane and an anthracycline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles |
| DRUG | Capecitabine | Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles |
| DRUG | Vinorelbine | Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2007-02-05
- Last updated
- 2009-09-28
Locations
10 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00431106. Inclusion in this directory is not an endorsement.